Business Wire

TX-ZILLIANT

19.4.2022 13:02:09 CEST | Business Wire | Press release

Share
Zilliant Unveils Next-Generation Price IQ®: The Market’s Fastest and Most Transparent Price Optimization Application

Zilliant , the industry leader in intelligent end-to-end pricing solutions and sales guidance software, today announced Next-Generation Price IQ® , the next giant leap for its market-leading B2B price optimization solution.

Inflation has become the new business reality, exacerbated by supply chain turmoil, increased competition, and dramatic swings in both demand and inventory availability. As a result, B2B companies need a faster, more powerful approach to pricing that maintains market alignment while generating prices that are easily explainable and defensible.

Next-Generation Price IQ® delivers huge advances in performance, with a 10x improvement in AI-based optimization speeds. Now, businesses can quickly respond to rapidly changing business dynamics and market changes while providing unprecedented price transparency to sales teams.

“Leading the market in price optimization for two decades has revealed one critical truth: If sales reps don’t understand how a price is generated, they are unlikely to use it,” said Zilliant President and Chief Executive Officer Greg Peters. “That’s why I’m thrilled to announce today that Next-Generation Price IQ® provides a way to keep prices competitive amid near-constant change while also providing a pragmatic means to leverage AI with a crystal-clear view into how prices were derived.”

Other B2B pricing solutions make it impossible to understand how pricing was derived by tucking parameters, complex AI, and formulas out of sight and out of reach for users, or they generate pricing using strict rules that break as complexity increases. These methods fail to address volatile and competitive B2B markets.

In stark contrast, Next-Generation Price IQ® offers a transparent, proven and pragmatic pricing solution using data science and AI that’s both sophisticated and flexible. Most importantly, Zilliant is helping embroiled B2B companies navigate a supply-constrained, pandemic-disrupted, and inflationary time to meet and exceed their margin and revenue goals.

Zilliant’s next generation of price optimization empowers pricing teams to:

  • Conduct goal-seeking, what-if scenarios to align business goals with pricing strategies
  • Enforce rational price relationships such as minimum margin requirements and good-better-best product relationships
  • Simultaneously visualize the predicted margin, revenue and volume impacts for various what-if scenarios before publishing optimized prices
  • View precisely how the optimization engine produced each price, drill into each optimized price, view the associated transactions with inline analytics, make adjustments, and see how price changes will impact revenue and profit
  • Immediately publish prices into CRM, CPQ, ERP, eCommerce or any other commercial system

No other price optimization solution in B2B can measure price elasticity, enforce rational price relationships, and conduct goal-seeking what-if scenarios in B2B. Where other applications use sequential rules or if-then statements, Next-Generation Price IQ® takes full advantage of constraint-based optimization to simultaneously account for business rules and price relationship requirements. Additionally, Zilliant is the only price optimization and management software company to offer a dedicated customer success team of industry, pricing, and data science experts to act as a strategic partner, delivering continuous value, change management guidance and precise measurement of adoption metrics, margin and revenue drivers, KPI trends, and pricing opportunity analyses.

Customers have reported a 10x ROI in less than a year with Zilliant’s price optimization solution; Next-Generation Price IQ® can be up and running in 90 days and lowers overall cost by supporting multiple pricing models and scenario templates, enabling simultaneous optimization of multiple lines of business within the same instance.

To learn more about Next-Generation Price IQ® , visit https://www.zilliant.com/products/priceiq .

About Zilliant

Zilliant powers intelligent commerce for B2B companies by connecting their commercial strategies with effective execution. Our industry-leading price optimization and management and sales guidance software enables profitable growth by transforming the way our customers use data to price and sell in traditional and digital channels. Zilliant’s data science, cloud-native software and passion for customer success delivers the highest ROI, fastest time to value and highest customer satisfaction. Learn more about how Zilliant helps power intelligence commerce at www.zilliant.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye